Exact Sciences Co. (NASDAQ:EXAS) EVP Sells $65,030.00 in Stock

Exact Sciences Co. (NASDAQ:EXAS) EVP Brian Baranick sold 929 shares of the stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $70.00, for a total transaction of $65,030.00. Following the transaction, the executive vice president now owns 13,687 shares of the company’s stock, valued at approximately $958,090. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Exact Sciences Trading Down 1.0 %

NASDAQ EXAS opened at $70.09 on Friday. The stock has a market cap of $12.93 billion, a PE ratio of -53.10 and a beta of 1.26. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The company’s 50-day moving average price is $57.32 and its 200-day moving average price is $55.84. The company has a current ratio of 2.17, a quick ratio of 1.98 and a debt-to-equity ratio of 0.73.

Exact Sciences (NASDAQ:EXAS) last issued its earnings results on Wednesday, July 31st. The medical research company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. Exact Sciences had a negative net margin of 6.70% and a negative return on equity of 4.97%. The business had revenue of $699.26 million for the quarter, compared to the consensus estimate of $690.02 million. During the same period in the prior year, the firm earned ($0.45) EPS. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. Equities research analysts forecast that Exact Sciences Co. will post -0.87 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of EXAS. Dimensional Fund Advisors LP grew its position in shares of Exact Sciences by 3.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 695,542 shares of the medical research company’s stock worth $51,466,000 after buying an additional 24,259 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in Exact Sciences by 5.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 14,901 shares of the medical research company’s stock worth $1,102,000 after acquiring an additional 759 shares during the period. Quadrant Capital Group LLC lifted its stake in Exact Sciences by 36.7% in the fourth quarter. Quadrant Capital Group LLC now owns 1,230 shares of the medical research company’s stock worth $91,000 after acquiring an additional 330 shares during the period. Norges Bank bought a new position in Exact Sciences during the 4th quarter worth about $120,308,000. Finally, PNC Financial Services Group Inc. increased its position in Exact Sciences by 30.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 18,191 shares of the medical research company’s stock valued at $1,346,000 after purchasing an additional 4,258 shares during the period. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EXAS has been the subject of a number of analyst reports. Benchmark lowered their price target on shares of Exact Sciences from $91.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, August 1st. The Goldman Sachs Group lowered their price objective on Exact Sciences from $88.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, July 17th. Canaccord Genuity Group reissued a “buy” rating and set a $75.00 target price on shares of Exact Sciences in a research report on Friday, September 13th. Evercore ISI decreased their price target on Exact Sciences from $80.00 to $72.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Finally, Scotiabank began coverage on shares of Exact Sciences in a research note on Thursday, June 27th. They set a “sector outperform” rating and a $70.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $78.14.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.